Chemotherapy-related thinking and memory changes during treatment for blood cancers

Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies

This project will follow adults with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma who are receiving first-line fixed-duration chemotherapy to see how common and how severe chemotherapy-related thinking and memory problems are compared with a close relative.

Quick facts

• Study type: Observational
• Enrollment: 120 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University Hospital, Angers (Government)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Angers, Maine et Loire)
• Trial ID: NCT07147621 on ClinicalTrials.gov

What this trial studies

This is an observational, single-center project enrolling adult patients with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma who are receiving fixed-duration first-line chemotherapy and their matched relatives as controls. The protocol is designed to document cognitive symptoms such as memory problems, slowed thinking, attention and language difficulties using standardized tests and questionnaires at baseline and follow-up timepoints during treatment. Key exclusions include known or suspected cognitive disorders prior to chemotherapy and severe neurological or psychiatric disease. The comparison with a closely matched relative control aims to help isolate chemotherapy-related effects on cognition.

Who should consider this trial

Good fit: Adults with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma who are receiving a fixed-duration first-line chemotherapy, can give informed consent, have social security coverage, and have a relative willing to participate as a matched control are ideal candidates.

Not a fit: Patients with pre-existing cognitive impairment, a history of severe neurological or psychiatric disorders, those without an eligible relative for the control group, or those not on fixed-duration first-line chemotherapy are unlikely to gain benefit from participation.

Why it matters

Potential benefit: If successful, the project could clarify how chemotherapy affects thinking and memory in blood-cancer patients and support better monitoring and supportive care to preserve quality of life.

How similar studies have performed: Chemotherapy-related cognitive changes have been well documented in solid tumors, particularly breast cancer, while data in hematological malignancies are scarce but point toward similar effects.

Eligibility criteria

Inclusion Criteria:

* Patient group inclusion criteria:

  * adult patient with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma;
  * patient receiving a fixed-duration first-line chemotherapy;
  * patient affiliated or beneficiary of a social security scheme; .signed inform consent form.
* Control group inclusion criteria:

  * adult;
  * patient's relative (spouse, brother, sister, friend, etc.);
  * less than 5 years of difference with the patient;
  * same educational level (\< baccalaureate/high school degree, baccalaureate/high school degree level, 2-year university degree, \> 2-year university degree);
  * person affiliated or beneficiary of a social security scheme;
  * signed informed consent form

Exclusion Criteria:

* Patient group exclusion criteria:

  * no patient's relative for the control group;
  * known or suspective cognitive disorders prior to chemotherapy;
  * history of severe neurological or psychiatric disorders (e.g., severe depression); .previous chemotherapy;
  * previous brain radiotherapy;
  * ongoing treatments affecting cognition;
  * patient unable to read;
  * patient not speaking French;
  * person deprived of liberty by judicial or administrative decision;
  * person under forced psychiatric care;
  * person under legal protection measures;
  * person unable to express consent; .pregnant or breastfeeding woman.
* Control group exclusion criteria:

  * known or suspected cognitive disorders;
  * history of severe neurological or psychiatric disorder (e.g., severe depression); .previous chemotherapy;
  * previous brain radiotherapy;
  * ongoing treatments affecting cognition;
  * person unable to read;
  * person not speaking French;
  * person deprived of liberty by judicial or administrative decision;
  * person under forced psychiatric care;
  * person under legal protection measures;
  * person unable to express consent;
  * pregnant or breastfeeding woman."

Where this trial is running

Angers, Maine et Loire

• University Hospital of Angers — Angers, Maine et Loire, France (Recruiting)

Study contacts

• Study coordinator: SCHMIDT ALINE, MD, PhD

Conditions Acute Myeloid Leukemia; Hodgkin' s Lymphoma; Non-Hodgkin&#39